RT Journal Article
SR Electronic
T1 Frequency and Potential Risk Factors Associated with the Development of Asymptomatic T2 Hyperintense Cervical Spine Lesions on MRI in Patients with Relapsing-Remitting Multiple Sclerosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.24.24314299
DO 10.1101/2024.09.24.24314299
A1 Fadlallah, Yasser
A1 Wang, Yujie
A1 Malik, Muhammad Taimur
A1 Tian, Fan
A1 Calabresi, Peter A.
A1 Izbudak, Izlem
A1 Huang, Yishang
A1 Fitzgerald, Kathryn C.
A1 Mowry, Ellen M.
YR 2024
UL http://medrxiv.org/content/early/2024/09/25/2024.09.24.24314299.abstract
AB Background Multiple sclerosis (MS) is one of the most common non-traumatic neurologic disorders affecting young adults in the United States. Brain MRI is an important tool for monitoring disease activity and treatment efficacy in people with MS. Spinal cord (SC) imaging has been less consistently used for monitoring inflammatory disease activity, and the frequency of clinically silent breakthrough disease in the SC is still unknown. Given the particular vulnerability of the cervical spinal cord (c-SC) to inflammatory demyelination, it is important to evaluate the necessity of routine c-SC scanning or to ascertain appropriate strategies for its monitoring, considering the burden of each scan on a person with MS, including scanner discomfort and cost.Objective To determine how frequently follow-up magnetic resonance imaging (MRI) of the cervical spinal cord (c-SC) in patients with relapsing remitting multiple sclerosis (RRMS) reveals asymptomatic T2 hyperintense lesions, either in combination or in the absence of new MRI brain lesions, and to identify potential associated risk factors for developing such lesions.Methods Patients aged 18-65 years who were diagnosed with RRMS and were seen in longitudinal follow-up at the Johns Hopkins MS Center from January 1, 2014, to December 1, 2019, with an MRI brain and C spine performed during that period, were included. The results of up to four c-SC scans were considered during this study period. Asymptomatic new lesions were identified as new hyperintense T2 lesions, with or without enhancement, observed on MRI during routine follow-up surveillance. Univariate and multivariable-adjusted logistic regression (sex at birth, age, race, and current disease modifying therapy [DMT] category) were employed to identify factors associated with the development of an asymptomatic c-SC lesion for the first scan. Additionally, a mixed-effects logistic regression analysis was performed to assess factors associated with developing asymptomatic lesions across successive scans.Results A total of 869 individuals were included in the cohort, contributing a median of 3 (interquartile range: 2,4) scans per person. The proportion of incidental asymptomatic lesions identified ranged from 4.8 to 12.1% across the four scans analyzed in the study. Among those with new lesions in the c-SC, roughly half also showed concomitant new activity on brain MRI. The multivariate model was notable for Black/African Americans having higher odds of an asymptomatic new lesion (OR= 3.26, 95% CI 0.79, 5.93, p<0.0001), a result that persisted in mixed effects logistic regression models (OR = 1.73, 95% CI = 1.27, 2.35, p = 0.001). Higher-efficacy therapies were associated with higher odds of detection of a new lesion in the mixed-effects model, an association that was not present when considering just the first scan results as the outcome.Conclusion While the association of higher-efficacy therapy is presumed to be related to confounding by indication, Black/African American individuals with MS appear to be at higher risk of developing an asymptomatic c-SC lesion on MRI surveillance, which could suggest higher value of ordering asymptomatic screening imaging of the cord in this subpopulation. Ultimately, however, a very small percentage of the overall population of those with MS has a new cord lesion in the absence of symptoms, and half of those have a new lesion on screening brain MRI. These findings should motivate the creation and validation of predictive models to inform the utility cord imaging at a given timepoint for a given individual with MS, which could enhance healthcare quality and reduce costs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Johns Hopkins School of Medicine gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.